Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kyowa Kirin Aims to Raise Core Margin to 30% on Late-Stage Launches
Kyowa Kirin aims to lift its core operating margin to 30% in the early 2030s by accelerating the launches of late-stage assets including rocatinlimab and ziftomenib, the company said on February 10. The target forms part of its Vision 2030 and Beyond strategy...
To read the full story
Related Article
- Kyowa Kirin Keeps Long-Term KPIs despite OX40 Setback, Ups 2026 Core Profit Outlook
May 11, 2026
- Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
March 5, 2026
- Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
March 4, 2026
- Kyowa Kirin Targets 20-Plus New Pipeline Assets by Early 2030s
February 10, 2026
BUSINESS
- Gilead Files CAR-T Therapy Tecartus in Japan for MCL, B-ALL
August 21, 2026
- Tiger, Gaudi Develop Compact Cell Transport Container
August 21, 2026
- Sawai’s Solo Tenelia Copy Raises Patent Questions Ahead of December Listing
August 21, 2026
- DT-Axis Charts Path to 2nd-Stage DTx Approval with Depression App
August 21, 2026
- Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…